UNSPSC 51111869: Trilostane

This classification denotes a 3-hydroxysteroid dehydrogenase inhibitor and steroidal aromatase inhibitor and anti-adrenal with the molecular formula C20H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0FPV48Q5R, chemically known as 5-alpha-androstane-2-alpha-carbonitrile, 4-alpha,5-epoxy-17-beta-hydroxy-3-oxo- but generally known as trilostane, which bears US NIH Compound Identifier 26163. European Medicines Agency schedules Trilostane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11297MIG.

UNSPSC 51111869 Trilostane, a Commodity code, encompasses pharmaceutical products distributed through state and local procurement systems, with recent activity driven by multistate cooperative purchasing agreements seeking generic pharmaceuticals and over-the-counter products for government facilities. State and local governments buy trilostane and related pharmaceutical commodities principally through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and distribute through authorized pharmaceutical wholesalers. Issuing bodies under this code include state health and human services departments, correctional systems, state hospitals, and other public facilities that source medications through centralized procurement channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is a representative repeat buyer, administering cooperative contracts on behalf of participating state and local entities including Oregon.

The Minnesota Department of Administration's Office of State Procurement, acting through MMCAP, posted an RFP on January 20, 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The RFP requires vendors to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, and to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Vendors must submit detailed product information by NDC code, SKU, and UPC; maintain commercial general liability insurance of $5,000,000 per occurrence; and accept a 3 percent administrative fee on all purchases. The evaluation weights price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and fee structure acceptance. Contract awards become effective July 1, 2026, with a two-year term for new responders and optional extensions at MMCAP's discretion. The solicitation supports multi-awards based on therapeutic considerations and member-specific needs.